C4 Therapeutics Launches With $73M Series A For New Can...
[http://medcitynews.com/2016/01/c4-therapeutics-launches-with-73m-series-a-for-new-cancer-treatment-approach/] The startup created from Dana-Farber cancer Institute announce...
[http://medcitynews.com/2016/01/c4-therapeutics-launches-with-73m-series-a-for-new-cancer-treatment-approach/] The startup created from Dana-Farber cancer Institute announce...
BACKGROUND Endometriosis, the growth of endometrial tissue outside the uterine cavity, is associated with chronic pelvic pain, subfertility and an increased risk of ovarian c...
http://humupd.oxfordjournals.org/cgi/content/short/dmv060v1?rss=1
Three years after Ann Arbor, MI-based Atterocor got started with a lead program for adrenal cancer, the biotech is now ready to launch into its next big stage of development a...
Halozyme therapeutics Inc. announced Monday that it has entered into a $150 million credit agreement to fund the start of its Phase 3 study in pancreatic cancer.
http://sdbj.com/news/2016/jan/04/halozyme-announces-150-million-credit-agreement-fu/
PRESS RELEASE The world’s largest database for cancer drug discovery has been revolutionised by adding 3D structures of faulty proteins and maps of cancer’s communicatio...
Gram-positive bacterial infections are an important cause of morbidity and death among cancer patients, despite current therapy. In this case-control study, we evaluated the c...
1. SUMMARY Monoclonal antibodies targeted against the proprotein convertase subtilisin kexin type 9 (PCSK9) protein increase the liver’s ability to remove low-density lipop...
https://www.cadth.ca/pcsk9-inhibitor-monoclonal-antibodies-treatment-hypercholesterolemia
Adaptimmune therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, has announced that it has initiated a Phase I/II study of its...
In the years since the human genome was first sequenced, a trove of genomic data has been amassed, aiding not only in our understanding of how the body works, but also in the ...
http://medicalxpress.com/news/2015-12-harnessing-chemical-genomic-cancer.html
Columbia University start-up Kyras therapeutics has closed a Series A financing to support the development and commercialization of its novel cancer therapeutic technology. Co...